Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abasaglar

- PMLiVE

Boehringer’s spesolimab shows promise in generalised pustular psoriasis prevention

The therapy prevented flares in patients with the chronic skin disease for over 48 weeks

- PMLiVE

Eli Lilly to acquire Sigilon in deal worth over $300m

The companies have been working together since 2018 on cell therapies for type 1 diabetes

- PMLiVE

Sanofi’s amlitelimab shows promise in phase 2b atopic dermatitis trial

The inflammatory skin disease affects an estimated 16.5 million adults in the US

- PMLiVE

Sanofi and Sobi’s haemophilia A treatment shows effective bleed protection in children

Current factor VIII therapies usually require patients to receive treatment multiple times a week

- PMLiVE

Eli Lilly to acquire Dice Therapeutics for approximately $2.4bn

The deal marks a significant expansion to Lilly's immunology pipeline

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants

RSV is the leading cause of hospitalisation for infants aged under one year in the US

- PMLiVE

Sanofi’s frexalimab shows promise in relapsing forms of MS

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

Approximately 300,000 people in the US live with uncontrolled COPD with evidence of type 2 inflammation

- PMLiVE

Sandoz and Just-Evotec Biologics announce multi-year biosimilar partnership

The Novartis unit will aim to expand its current pipeline of biosimilars to about 24 candidates

- PMLiVE

Positive results for Sanofi/Regeneron’s Dupixent published in Nature Medicine

The biologic was shown to significantly improve uncontrolled prurigo nodularis symptoms

- PMLiVE

Eli Lilly’s Alzheimer’s drug shown to significantly slow disease progression in phase 3 trial

Donanemab slowed the progression of early Alzheimer’s disease by 35% compared to placebo

- PMLiVE

Almirall and Eli Lilly’s lebrikizumab shows continued improvement in atopic dermatitis

The common inflammatory skin disease affects over 4% of adults in the EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links